The growth of most prostate cancers is initially dependent on signaling via the androgen receptor (AR) and the standard systemic treatment for late stage prostate cancer, androgen deprivation therapy (ADT), involves the blocking of AR signaling by reducing the levels of circulating androgens by chemical means. This evidence concerns the gene AR and prostate carcinoma.